Targeting the disordered C terminus of PTP1B with an allosteric inhibitor

Nature Chemical Biology

Volumn 10, Issue 7, 2014, Pages 558-566

  Krishnan, Navasona ^a   Koveal, Dorothy ^b   Miller, Daniel H ^c,d   Xue, Bin ^a,g   Akshinthala, Sai Dipikaa ^a   Kragelj, Jaka ^e   Jensen, Malene Ringkjøbing ^e   Gauss, Carla Maria ^a   Page, Rebecca ^b   Blackledge, Martin ^e   Muthuswamy, Senthil K ^a,f   Peti, Wolfgang ^c,d   Tonks, Nicholas K ^a  

^a Howard Hughes Medical Institute Cold Spring Harbor Laboratory Cold Spring Harbor   (United States)

^b BROWN UNIVERSITY   (United States)

^c BROWN UNIVERSITY   (United States)

^d BROWN UNIVERSITY   (United States)

^e INSTITUT DE BIOLOGIE STRUCTURALE   (France)

^f UNIVERSITY OF TORONTO   (Canada)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN TYROSINE PHOSPHATASE 1B; TRODUSQUEMINE;

ALLOSTERISM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; CONTROLLED STUDY; METASTASIS; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN TARGETING; SIGNAL TRANSDUCTION;

ALLOSTERIC REGULATION; ALLOSTERIC SITE; ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CATALYTIC DOMAIN; CHOLESTANES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KINETICS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MODELS, MOLECULAR; MOLECULAR TARGETED THERAPY; PROTEIN BINDING; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 1; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; SPERMINE;

EID: 84902852963     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nchembio.1528     Document Type: Article

References (45)

1. Slamon, D.J. et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244, 707-712 (1989).
2. Tiwari, R.K., Borgen, P.I., Wong, G.Y., Cordon-Cardo, C. & Osborne, M.P. HER-2/neu amplification and overexpression in primary human breast cancer is associated with early metastasis. Anticancer Res. 12, 419-425 (1992).
3. Engelman, J.A. & Settleman, J. Acquired resistance to tyrosine kinase inhibitors during cancer therapy. Curr. Opin. Genet. Dev. 18, 73-79 (2008).
4. Rexer, B.N. & Arteaga, C.L. Intrinsic and acquired resistance to HER2-Targeted therapies in HER2 gene-Amplified breast cancer: Mechanisms and clinical implications. Crit. Rev. Oncog. 17, 1-16 (2012).
5. Tonks, N.K. Protein tyrosine phosphatases-from housekeeping enzymes to master regulators of signal transduction. FEBS J. 280, 346-378 (2013).
6. Andersen, J.N. & Tonks, N.K. Protein tyrosine phosphatase-based therapeutics: Lessons from PTP1B. Top. Curr. Genet. 5, 201-230 (2004).
7. Julien, S.G. et al. Protein tyrosine phosphatase 1B deficiency or inhibition delays ErbB2-induced mammary tumorigenesis and protects from lung metastasis. Nat. Genet. 39, 338-346 (2007).
8. Bentires-Alj, M. & Neel, B.G. Protein-Tyrosine phosphatase 1B is required for HER2/Neu-induced breast cancer. Cancer Res. 67, 2420-2424 (2007).
9. Tonks, N.K., Diltz, C.D. & Fischer, E.H. Purification of the major protein-Tyrosine-phosphatases of human placenta. J. Biol. Chem. 263, 6722-6730 (1988).
10. Hao, L., Tiganis, T., Tonks, N.K. & Charbonneau, H. The noncatalytic C-Terminal segment of the T cell protein tyrosine phosphatase regulates activity via an intramolecular mechanism. J. Biol. Chem. 272, 29322-29329 (1997).
11. Lantz, K.A. et al. Inhibition of PTP1B by trodusquemine (MSI-1436) causes fat-specific weight loss in diet-induced obese mice. Obesity (Silver Spring) 18, 1516-1523 (2010).
12. Wiesmann, C. et al. Allosteric inhibition of protein tyrosine phosphatase 1B. Nat. Struct. Mol. Biol. 11, 730-737 (2004).
13. Metallo, S.J. Intrinsically disordered proteins are potential drug targets. Curr. Opin. Chem. Biol. 14, 481-488 (2010).
14. Cuchillo, R. & Michel, J. Mechanisms of small-molecule binding to intrinsically disordered proteins. Biochem. Soc. Trans. 40, 1004-1008 (2012).
15. Pervushin, K., Riek, R., Wider, G. & Wuthrich, K. Attenuated T2 relaxation by mutual cancellation of dipole-dipole coupling and chemical shift anisotropy indicates an avenue to NMR structures of very large biological macromolecules in solution. Proc. Natl. Acad. Sci. USA 94, 12366-12371 (1997).
16. Zhang, H., Neal, S. & Wishart, D.S. RefDB: A database of uniformly referenced protein chemical shifts. J. Biomol. NMR 25, 173-195 (2003).
17. Barford, D., Flint, A.J. & Tonks, N.K. Crystal structure of human protein tyrosine phosphatase 1B. Science 263, 1397-1404 (1994).
18. Muthuswamy, S.K., Li, D., Lelievre, S., Bissell, M.J. & Brugge, J.S. ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini. Nat. Cell Biol. 3, 785-792 (2001).
19. Konecny, G.E. et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-Treated breast cancer cells. Cancer Res. 66, 1630-1639 (2006).
20. Siegel, P.M., Dankort, D.L., Hardy, W.R. & Muller, W.J. Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors. Mol. Cell. Biol. 14, 7068-7077 (1994).
21. Dubé, N., Cheng, A. & Tremblay, M.L. The role of protein tyrosine phosphatase 1B in Ras signaling. Proc. Natl. Acad. Sci. USA 101, 1834-1839 (2004).
22. Julien, S.G., Dube, N., Hardy, S. & Tremblay, M.L. Inside the human cancer tyrosine phosphatome. Nat. Rev. Cancer 11, 35-49 (2011).
23. Sangwan, V. et al. Protein-Tyrosine phosphatase 1B modulates early endosome fusion and trafficking of Met and epidermal growth factor receptors. J. Biol. Chem. 286, 45000-45013 (2011).
24. Brown-Shimer, S. et al. Molecular cloning and chromosome mapping of the human gene encoding protein phosphotyrosyl phosphatase 1B. Proc. Natl. Acad. Sci. USA 87, 5148-5152 (1990).
25. Tonks, N.K. & Muthuswamy, S.K. A brake becomes an accelerator: PTP1B-A new therapeutic target for breast cancer. Cancer Cell 11, 214-216 (2007).
26. Wiener, J.R. et al. Overexpression of the protein tyrosine phosphatase PTP1B in human breast cancer: Association with p185c-erbB-2 protein expression. J. Natl. Cancer Inst. 86, 372-378 (1994).
27. Wang, J., Chen, X., Liu, B. & Zhu, Z. Suppression of PTP1B in gastric cancer cells in vitro induces a change in the genome-wide expression profile and inhibits gastric cancer cell growth. Cell Biol. Int. 34, 747-753 (2010).
28. Wang, J. et al. PTP1B expression contributes to gastric cancer progression. Med. Oncol. 29, 948-956 (2012).
29. Lessard, L. et al. PTP1B is an androgen receptor-regulated phosphatase that promotes the progression of prostate cancer. Cancer Res. 72, 1529-1537 (2012).
30. Zhu, S., Bjorge, J.D. & Fujita, D.J. PTP1B contributes to the oncogenic properties of colon cancer cells through Src activation. Cancer Res. 67, 10129-10137 (2007).
31. Johnson, K.J. et al. PTP1B suppresses prolactin activation of Stat5 in breast cancer cells. Am. J. Pathol. 177, 2971-2983 (2010).
32. Balavenkatraman, K.K. et al. Epithelial protein-Tyrosine phosphatase 1B contributes to the induction of mammary tumors by HER2/Neu but is not essential for tumor maintenance. Mol. Cancer Res. 9, 1377-1384 (2011).
33. He, R., Zeng, L.F., He, Y., Zhang, S. & Zhang, Z.Y. Small molecule tools for functional interrogation of protein tyrosine phosphatases. FEBS J. 280, 731-750 (2013).
34. Kane, R.C. et al. Sorafenib for the treatment of advanced renal cell carcinoma. Clin. Cancer Res. 12, 7271-7278 (2006).
35. Wiede, F. et al. T cell protein tyrosine phosphatase attenuates T cell signaling to maintain tolerance in mice. J. Clin. Invest. 121, 4758-4774 (2011).
36. Tiganis, T. PTP1B and TCPTP-nonredundant phosphatases in insulin signaling and glucose homeostasis. FEBS J. 280, 445-458 (2013).
37. Galic, S. et al. Coordinated regulation of insulin signaling by the protein tyrosine phosphatases PTP1B and TCPTP. Mol. Cell. Biol. 25, 819-829 (2005).
38. Hanson, M.A. et al. A specific cholesterol binding site is established by the 2.8 Å structure of the human ß2-Adrenergic receptor. Structure 16, 897-905 (2008).
39. Zhang, J. et al. Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature 463, 501-506 (2010).
40. Hammoudeh, D.I., Follis, A.V., Prochownik, E.V. & Metallo, S.J. Multiple independent binding sites for small-molecule inhibitors on the oncoprotein c-Myc. J. Am. Chem. Soc. 131, 7390-7401 (2009).
41. Agulnik, M. et al. Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. J. Clin. Oncol. 25, 3978-3984 (2007).
42. Hinow, P., Wang, S.E., Arteaga, C.L. & Webb, G.F. Relocating job wise? A mathematical model separates quantitatively the cytostatic and cytotoxic effects of a HER2 tyrosine kinase inhibitor. Theor. Biol. Med. Model. 4, 14 (2007).
43. Jänne, P.A., Taffaro, M.L., Salgia, R. & Johnson, B.E. Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma. Cancer Res. 62, 5242-5247 (2002).
44. Meng, T.C., Hsu, J.S.F. & Tonks, N.K. Development of a modified in-gel assay to identify protein tyrosine phosphatases that are oxidized and inactivated in vivo. Methods 35, 28-36 (2005).
45. Lin, G., Aranda, V., Muthuswamy, S.K. & Tonks, N.K. Identification of PTPN23 as a novel regulator of cell invasion in mammary epithelial cells from a loss-of-function screen of the 'PTP-ome'. Genes Dev. 25, 1412-1425 (2011).